SCHEMBL30174644

SCHEMBL30174644

CC(C)(C)OC(=O)N(CCO)Cc1ccccc1O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.50
HDAC1 Q13547 3/20 0.39
HDAC3 O15379 2/20 0.39
HDAC2 Q92769 2/20 0.39
NCOR2 Q9Y618 2/20 0.39
AKR1B1 P15121 1/20 0.38
CA14 Q9ULX7 1/20 0.36
MEN1 O00255 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HTR1A P08908 1/20 0.36
KDM1A O60341 1/20 0.34
HSPA5 P11021 1/20 0.34
AKT1 P31749 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25516985 1.00 SSTR4 (0.50) SSTR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL1235982 0.89 HTR1A (0.45) SSTR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL16701734 0.84 SSTR4 (0.55) SSTR4MEN1KMT2ACTSS
SCHEMBL7852494 0.84 SSTR4 (0.52) SSTR4RECQLL3MBTL1
SCHEMBL30174862 0.84 SSTR4 (0.46) SSTR4AKR1B1MEN1KMT2AHSPA5
SCHEMBL25516873 0.84 SSTR4 (0.46) SSTR4AKR1B1MEN1KMT2AHSPA5
SCHEMBL15055377 0.83 SSTR4 (0.54) SSTR4HDAC1CA14RECQLL3MBTL1
SCHEMBL2112935 0.82 HDAC3 (0.54) SSTR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL2979243 0.81 SSTR4 (0.55) SSTR4HDAC1HDAC3HDAC2NCOR2
SCHEMBL3942906 0.81 SSTR4 (0.44) SSTR4HDAC1HDAC3HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
EP-4132944-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2023-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 SSTR4 3440/4885HDAC1 2076/4885HDAC3 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.